FDA Approves Reduced Monitoring Time for IMDELLTRA® Treatment Doses in Lung Cancer Patients #USA #Amgen #Thousand_Oaks #IMDELLTRA® #ES-SCLC
@newsen.bsky.social
@newsen.bsky.socialFDA Approves Reduced Monitoring Time for IMDELLTRA® Treatment Doses in Lung Cancer Patients #USA #Amgen #Thousand_Oaks #IMDELLTRA® #ES-SCLC
@pharmaphorum.bsky.social#Amgen's fast-growing cancer #immunotherapy #Imdelltra could move into the first-line setting in #smallcelllungcancer (SCLC), after delivering as a #dualregimen with AstraZeneca's Imfinzi in the DeLLphi-305 study.
@medchemexpress.bsky.social🚨Phase 3 DeLLphi-305 showed that #tarlatamab-dlle (#IMDELLTRA, Amgen) + #durvalumab (#IMFINZI, AstraZeneca) significantly improved overall survival versus durvalumab alone in the first-line maintenance setting.
@newsen.bsky.socialSignificant Survival Improvement in Extensive Stage Small Cell Lung Cancer with IMDELLTRA and IMFINZI Combination #USA #Thousand_Oaks #SCLC #IMDELLTRA #IMFINZI